Thrive Pharmacy Recalls Subpotent Buprenorphine Troches in Florida
Thrive Pharmacy is recalling 89 Buprenorphine Black Cherry 2 mg troches in Florida because the medication was found to be subpotent.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for significant injury or health risk potential.
Plain-English summary
Thrive Pharmacy, a pharmacy located in Jacksonville, Florida, is voluntarily recalling 89 Buprenorphine Black Cherry 2 mg troches. The product is supplied in plastic troche molds with a cardboard outer sleeve. The specific lot affected is 191217A, with an expiration date of 06/14/2020.
The recall was initiated because the medication was found to be subpotent, meaning it did not contain the full amount of the active ingredient as labeled. The recall is limited to the state of Florida. The recall was initiated on March 10, 2020, and was classified as Class II by the FDA.
Consumers who have this specific lot of Buprenorphine troches should stop using them and contact their healthcare provider or the pharmacy for further instructions. The recall was terminated on June 2, 2023.
The recalled product
- Product
- Buprenorphine Black Cherry 2 mg Troche, supplied in plastic troche molds with cardboard outer sleeve, Thrive Pharmacy 2863 St Johns Bluff RD. South # 135 Jacksonville, Florida
- Manufacturer
- Matthew 7:25 Inc dba Thrive Pharmacy
- Category
- Drug — Pharmaceutical
- Hazard
- Affected units
- 89
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 191217A Exp. 06/14/2020
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 3 recalled by Matthew 7:25 Inc dba Thrive Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Matthew 7:25 Inc dba Thrive Pharmacy
See all →- SevereThrive Pharmacy Recalls Subpotent Buprenorphine Troches in Florida
FDA (Drugs) · 2020-04-01
- SevereThrive Pharmacy Recalls Subpotent Buprenorphine Troches in Florida
FDA (Drugs) · 2020-04-01
Same hazard · subpotent drug
See all →- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
Similar recalls
- ModerateFerring Recalls Bravelle 75 IU Vials Due to Subpotent Drug
FDA (Drugs) · 2015-10-21
- LowBuspirone Hydrochloride Tablets 5 mg Recalled for Subpotency
FDA (Drugs) · 2026-05-13
- SevereTris Pharma Recalls Superpotent Infant Ibuprofen Suspension
FDA (Drugs) · 2019-02-20
- SevereTris Pharma Recalls Hydrocodone and Chlorpheniramine Suspension Due to Potency Issues
FDA (Drugs) · 2019-07-31
- ModerateMasterPharm Recalls Progesterone Troches Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateHikma Recalls Buprenorphine Hydrochloride Injection Due to Low Potency
FDA (Drugs) · 2020-09-02